Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00101985
Registration number
NCT00101985
Ethics application status
Date submitted
18/01/2005
Date registered
19/01/2005
Date last updated
13/04/2015
Titles & IDs
Public title
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
Query!
Scientific title
An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome
Query!
Secondary ID [1]
0
0
223412/068
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Irritable Colon
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - talnetant
Treatment: Drugs: talnetant
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Determine whether talnetant provided adequate relief from IBS pain and discomfort for at least one of three talnetant dose groups compared with placebo and to determine the safety and tolerability of talnetant in subjects with IBS.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
- Explore response among subgroups IBS. - Evaluate positive treatment effects within bowel subgroups. - Compare treatment groups for global improvement of IBS symptoms. - Improvement of IBS pain or discomfort, Quality of Life.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Subjects will be required to conduct self-assessments of their IBS symptoms using a
touch-tone telephone system for the duration of the study (15 weeks).
- Must be diagnosed with IBS consistent with the Rome II criteria.
- Must have normal results from a colonic procedure within 2 years of randomization.
- Must have conducted self-assessments on at least 12 days and have a documented average
IBS pain or discomfort score of greater than or equal to 1.5 during the two-week
screening phase.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Self-assessment of no stool for 7 days during the two-week screening phase.
- Clinically significant abnormal laboratory tests.
- Current evidence or history of various conditions, comorbidities, or surgeries such as
Irritable Bowel Disease (IBD), gastrointestinal surgeries, and diverticulitis.
- Inability to use the touch-tone telephone system.
- Hypersensitivity to quinolone antibiotics or quinolone derivatives.
- Diagnosis of a psychiatric disorder within the past 2 years and not on a stable dose
of medication for at least 6 months.
- Women who are pregnant, breast feeding, or planning to become pregnant during the
study.
Permitted medications: The subject is allowed to take any of the following medications,
provided they maintain a stable dose for at least 30 days prior to the Screening visit and
throughout the remainder of the study:
- Antidepressants, except REMERON
- Antihypercholesterolemics
- Iron supplements
- Bulking agents
- Fiber supplement
- Thyroid replacement therapy (levothyroxine)
- Antipsychotics
- Cox-2 inhibitors (CELEBREX)
Prohibited medications: Subjects must stop taking any medications they are taking to treat
their IBS symptoms and must not have taken any of the prohibited medications at least 7
days prior to the Screening visit and must remain off these medications for the duration of
the study.
- Anticholinergics (dicyclomine, hyoscyamine, propantheline)
- Cholinomimetic (bethanechol, pyridostigmine, tacrine, physostigmine)
- All narcotics (morphine, codeine, TYLENOL #3, propoxyphene, either alone or in
combination)
- Tramadol hydrochloride (ULTRAM)
- Colchicine
- Orlistat (XENICAL)
- Misoprostol, alone or in combination (ARTHROTEC, CYTOTEC)
- 5-HT3 receptor antagonists (ondansetron, tropisetron, dolasetron, granisetron,
mirtazapine, cilansetron, alosetron)
- Tegaserod (ZELNORM)
- Gabapentin
- Lupron
- Antacids containing magnesium or aluminium
- Antidiarrheal agents
- Bismuth compounds
- Prokinetic agents (cisapride, metoclopramide)
- Sulfasalazine
- Laxatives
- Cholestyramine
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2005
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
741
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Garran
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Concord
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Newtown
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Kippa Ring
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Spring Hill
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Bedford Park
Query!
Recruitment hospital [8]
0
0
GSK Investigational Site - Port Lincoln
Query!
Recruitment hospital [9]
0
0
GSK Investigational Site - Box Hill
Query!
Recruitment hospital [10]
0
0
GSK Investigational Site - Fitzroy
Query!
Recruitment hospital [11]
0
0
GSK Investigational Site - Malvern
Query!
Recruitment hospital [12]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2606 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [3]
0
0
2042 - Newtown
Query!
Recruitment postcode(s) [4]
0
0
4021 - Kippa Ring
Query!
Recruitment postcode(s) [5]
0
0
4000 - Spring Hill
Query!
Recruitment postcode(s) [6]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [8]
0
0
5606 - Port Lincoln
Query!
Recruitment postcode(s) [9]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [10]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [11]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [12]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nebraska
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Jersey
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Ohio
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oklahoma
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oregon
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Pennsylvania
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Tennessee
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Texas
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Utah
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Alberta
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Nova Scotia
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Saskatchewan
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Caen
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Clermont-Ferrand Cedex
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Grenoble Cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Issoire
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Marseille
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Miramas
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Nice
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Vitry sur Seine
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Sachsen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Schleswig-Holstein
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Berlin
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Hamburg
Query!
Country [49]
0
0
Netherlands
Query!
State/province [49]
0
0
Stadskanaal
Query!
Country [50]
0
0
South Africa
Query!
State/province [50]
0
0
Claremont
Query!
Country [51]
0
0
South Africa
Query!
State/province [51]
0
0
N1 City
Query!
Country [52]
0
0
South Africa
Query!
State/province [52]
0
0
Parktown
Query!
Country [53]
0
0
South Africa
Query!
State/province [53]
0
0
Somerset West
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Badalona
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Barcelona
Query!
Country [56]
0
0
Spain
Query!
State/province [56]
0
0
Madrid
Query!
Country [57]
0
0
Spain
Query!
State/province [57]
0
0
Oviedo
Query!
Country [58]
0
0
Sweden
Query!
State/province [58]
0
0
Göteborg
Query!
Country [59]
0
0
Sweden
Query!
State/province [59]
0
0
Nacka
Query!
Country [60]
0
0
Sweden
Query!
State/province [60]
0
0
Stockholm
Query!
Country [61]
0
0
United Kingdom
Query!
State/province [61]
0
0
Lancashire
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
Middlesex
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
Leeds
Query!
Country [64]
0
0
United Kingdom
Query!
State/province [64]
0
0
Portergate, Sheffield
Query!
Country [65]
0
0
Query!
State/province [65]
0
0
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the effectiveness and safety of the investigational drug talnetant
in treating subjects with irritable bowel syndrome (IBS).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00101985
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00101985
Download to PDF